Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
Public ClinicalTrials.gov record NCT00300950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients With Post-resection R0/R1 Pancreatic Cancer With Tumor Sequence Confirmation of Ras Mutations.
Study identification
- NCT ID
- NCT00300950
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlobeImmune
- Industry
- Enrollment
- 176 participants
Conditions and interventions
Conditions
Interventions
- GI-4000 Biological
- Gemcitabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2005
- Primary completion
- Jan 31, 2015
- Completion
- Jan 31, 2015
- Last update posted
- Apr 5, 2015
2006 – 2015
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Tower Cancer Research Foundation | Beverly Hills | California | 90211 | — |
| University of California San Diego | La Jolla | California | 92093 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Georgetown University Medical Center / Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Rush University Medical School | Chicago | Illinois | 60612 | — |
| Minnesota Oncology Hematology, PA | Minneapolis | Minnesota | 55404 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| State University of NY at Stony Brook | Stony Brook | New York | 11794 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Texas Oncology, PA | Dallas | Texas | 75231 | — |
| The Texas Cancer Center Dallas Southwest | Dallas | Texas | 75237 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| South Texas Oncology & Hematology | San Antonio | Texas | 78229 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Froedtert Multi-Disciplinary Cancer Clinic | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00300950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2015 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00300950 live on ClinicalTrials.gov.